Most real-world data (RWD) sets are based on claims data, which provides useful information, but misses the context of what takes place for a patient during a visit to a hospital or clinic. Premier Inc., a new Aetion data collaborator, offers a robust hospital chargemaster database with detailed information on the treatments, procedures, and devices used during a patient’s visit to a medical facility. Biopharma and government partners then use these data—which are sourced from over 1,000 medical facilities across the U.S. and report on one in every four or five U.S. patients—to answer key questions around drug costs, clinical outcomes, and utilization patterns.
We spoke with Myla Maloney, Vice President of Strategy and Commercial Operations, Applied Sciences at Premier, about what makes the Premier Healthcare Database unique, and how biopharma can leverage its chargemaster data to learn more about how their drugs perform in the real world—and how to demonstrate a treatment’s value to health care systems.
Read more to learn how biopharma can use chargemaster data to generate real-world evidence (RWE) on their treatments’ performance in real clinical practice, and how these data can uncover insights about COVID-19.